# Progress Note 04 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Swami Vivekananda (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI032-SYN-TD
- Date: 1898-03-23
- Fictional facility: St. Posthumous Health Center
- Fictional author: Anjali Thornbury-Mensah, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Five-week diabetes review before a long journey. **S**

## History of present illness

Swami Vivekananda returns five weeks after starting metformin and two weeks after starting losartan. His thirst has gone, he wakes to pass urine once a night or not at all, and his fasting readings are 128 to 150 mg/dL. He has had no dizziness on losartan; home blood pressure averages 128/80. He has seen the dietitian twice: he now takes a smaller portion of rice with more dal and vegetables, keeps the sweets offered after worship to a small piece, and has kept two fortnightly fasts with fruit, milk and water, with midday readings of 110 to 140 mg/dL. The screening tests from the preventive visit were negative for HIV, hepatitis C, hepatitis B surface antigen and tuberculosis infection, and he is not immune to hepatitis B. He has decided to take the statin. In a week he leaves for several months of travel and teaching in the mountains, and wants a plan he can follow far from the clinic. **S**

| Element | Detail |
|---|---|
| Glucose | Fasting 128 to 150 mg/dL; midday on fast days 110 to 140 mg/dL |
| Blood pressure | Home average 128/80 on losartan |
| Screening results | HIV, hepatitis C antibody, hepatitis B surface antigen and interferon-gamma release assay negative; hepatitis B surface antibody negative |
| Upcoming | Several months of travel in the mountains from next week |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy much better; weight 73.8 kg |
| Genitourinary | Negative | Nocturia once at most |
| Gastrointestinal | Negative | No loose stools |
| Psychiatric | Negative | Eager for the journey; sleep still slow to come |

4 systems reviewed. **S**

## Current medications

- Metformin extended-release 500 mg tablets: four tablets (1872 mg) with the evening meal; on fast days with the meal that ends the fast; hold if vomiting, diarrhea or unable to drink **S**
- Losartan 25 mg oral tablet, one tablet daily **S**
- Atorvastatin 10 mg oral tablet, one tablet daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 128/80 mmHg; pulse 74 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 73.8 kg; BMI 24.9 kg/m². All vital signs are synthetic.

Potassium: 4.6 mmol/L; Creatinine: 1 mg/dL; eGFR (CKD-EPI 1893): 101 mL/min/1.73 m²; Urine albumin-to-creatinine ratio: 41 mg/g (high). All results are synthetic.

## Change since baseline

- Potassium: 4.3 mmol/L at baseline, 4.6 mmol/L at this visit **S**
- Creatinine: 0.96 mg/dL at baseline, 1 mg/dL at this visit **S**
- eGFR (CKD-EPI 1893): 106 mL/min/1.73 m² at baseline, 101 mL/min/1.73 m² at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; weight 73.8 kg; blood pressure 128/80, pulse 74 |
| Eyes | Retinal photographs today: no retinopathy in either eye |
| Cardiovascular | Regular; no edema |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Type 2 diabetes, improving** (E11.65). Improving on metformin 1000 mg and his changed diet, with fasting readings still above 130. He chose to increase metformin to the full dose. A second medicine (an SGLT2 inhibitor) was discussed; because his albuminuria is not yet confirmed, and because a new medicine that adds fluid loss is unwise at the start of months of travel with fasting, he chose to wait and decide on his return. **S**
   - Metformin extended-release 1872 mg with the evening meal.
   - A1c in three months: at a laboratory where he is staying, or a home kit, with results sent to the clinic.
   - Sick-day rules: hold metformin and losartan if vomiting, diarrhea or unable to drink, and restart when eating.
   - Enough medicine, test strips and a printed summary for the journey; message the clinic with readings monthly.
2. **Moderately increased albuminuria** (R80.9). Second sample 41 mg/g; one more over three to six months will confirm it. **S**
   - Repeat in three months with the A1c.
3. **Hypertension** (I10). Home 128/80 on losartan; potassium 4.6 and creatinine 1.00, stable. **S**
   - Continue losartan 25 mg.
4. **Mixed hyperlipidemia** (E78.2). He chose a moderate-intensity statin. **S**
   - Atorvastatin 10 mg daily.
   - Lipid panel in six to twelve weeks.
5. **Fasting and travel**. His fasts with fruit, milk and water have gone safely on metformin. **S**
   - Continue the same rules; with glucose now steady below 180, a short waterless fast is possible if he drinks well before and after, checks glucose, and breaks it by the same thresholds; avoid waterless fasts in heat or at high altitude.
6. **Insomnia** (G47.00). Sleep diary: about two hours to fall asleep, five hours of sleep, rising before dawn for meditation; STOP-BANG 2 (low risk of sleep apnea). Insomnia Severity Index 15. **S**
   - Cognitive behavioral therapy for insomnia by video while he travels: a fixed rising time kept with his meditation, time in bed matched to sleep, and no reading or writing in bed.
   - No sleeping tablets, as he prefers.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | A1c | Quarterly until at goal and after a change in therapy | Due | Due in three months, during his travels; arrangements made |
| Laboratory | Potassium and creatinine after starting an ARB | One to two weeks after starting or changing the dose | Completed today | Potassium 4.6; creatinine 1.00; eGFR 101 |
| Laboratory | Urine albumin-to-creatinine ratio | Two of three abnormal over three to six months to confirm | Completed today | 41 mg/g, the second abnormal sample |
| Laboratory | Lipid panel after starting a statin | Four to twelve weeks after starting | Due | Statin started today; due in six to twelve weeks |
| Imaging | Retinal photographs | At diagnosis, then every one to two years | Completed today | No retinopathy in either eye |
| Examination | Blood pressure, weight and BMI | Every visit | Completed today | 128/80; home 128/80; weight 73.8 kg |
| Self-management | Medical nutrition therapy | At diagnosis and as needed | Completed today | Two dietitian visits; a mostly vegetarian plan of his choosing |
| Self-management | Fasting plan | Before any religious fast | Completed today | Fasts with fruit, milk and water went safely; travel rules agreed |
| Self-management | Sick-day rules | At diagnosis and before travel | Completed today | Hold metformin and losartan when vomiting, diarrhea or unable to drink |
| Self-management | Tobacco use | Every visit | Completed today | None |
| Self-management | Insomnia treatment | At diagnosis of chronic insomnia | Referred | Cognitive behavioral therapy for insomnia by video |

## Goal progress

- Diabetes confirmed and classified within a week. Outcome by 1898-02-16: Type 2 diabetes confirmed by A1c 9.4 percent and fasting glucose 172 mg/dL; GAD65 antibodies negative and C-peptide preserved. **S**
- A1c below 7 percent without hypoglycemia, in a way that fits his diet and fasts. In progress; target 1898-10-27. **S**
- Blood pressure below 130/80. Outcome by 1898-03-23: Home 128/80 and clinic 128/80 two weeks after starting losartan. **S**
- Albuminuria reduced and kidney function preserved. In progress; target 1899-01-26. **S**
- Falling asleep within 30 minutes on most nights. In progress; target 1898-12-08. **S**

## Medication changes

- Stopped: Metformin extended-release 500 mg tablets: two tablets (1000 mg) with the evening meal, starting with one for the first week **S**
- Started: Metformin extended-release 500 mg tablets: four tablets (1872 mg) with the evening meal; on fast days with the meal that ends the fast; hold if vomiting, diarrhea or unable to drink **S**
- Started: Atorvastatin 10 mg oral tablet, one tablet daily **S**

## Guideline basis

- CMID: Clinical Monitoring Intelligence Database, diabetes type 2, hypertension, hyperlipidemia, CKD and asthma monographs (2026), Aether Forge
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026 (2026), American Diabetes Association (Diabetes Care 2026;49(Suppl 1))
- 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2026 (2026), American Diabetes Association (Diabetes Care 2026;49(Suppl 1))
- 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2026 (2026), American Diabetes Association (Diabetes Care 2026;49(Suppl 1))
- 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes-2026 (2026), American Diabetes Association (Diabetes Care 2026;49(Suppl 1))
- 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026 (2026), American Diabetes Association (Diabetes Care 2026;49(Suppl 1))
- Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians (2016), American College of Physicians (Ann Intern Med 2016;165(2):125-133)
- Hassanein M, et al. Diabetes and Ramadan: Practical guidelines 2021. Diabetes Res Clin Pract 2022;185:109185 (PMID 35016991) (2021), International Diabetes Federation and the Diabetes and Ramadan International Alliance

## Follow-up

- Messages with home readings monthly while he travels. A1c, urine albumin and lipid panel in about three months wherever he is. Diabetes review on his return. **S**
- Next scheduled visit 1898-10-27: review after seven months away and a week after an asthma attack: A1c, kidneys, lipids, spirometry with bronchodilator response and FeNO; asthma and diabetic kidney disease confirmed; empagliflozin and maintenance-and-reliever inhaler; fasting plan for the coming festival. **S**
